Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

Similar articles for PubMed (Select 22964581)

1.

Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells.

Cui J, Germer K, Wu T, Wang J, Luo J, Wang SC, Wang Q, Zhang X.

Cancer Res. 2012 Nov 1;72(21):5625-34. doi: 10.1158/0008-5472.CAN-12-1305. Epub 2012 Sep 10.

2.

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R.

J Natl Cancer Inst. 2004 Jun 16;96(12):926-35.

3.

Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.

Leary AF, Drury S, Detre S, Pancholi S, Lykkesfeldt AE, Martin LA, Dowsett M, Johnston SR.

Clin Cancer Res. 2010 Mar 1;16(5):1486-97. doi: 10.1158/1078-0432.CCR-09-1764. Epub 2010 Feb 23.

4.

Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression.

Giordano C, Catalano S, Panza S, Vizza D, Barone I, Bonofiglio D, Gelsomino L, Rizza P, Fuqua SA, Andò S.

Oncogene. 2011 Sep 29;30(39):4129-40. doi: 10.1038/onc.2011.124. Epub 2011 Apr 18.

5.

Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.

Lindberg K, Helguero LA, Omoto Y, Gustafsson JÅ, Haldosén LA.

Breast Cancer Res. 2011 Apr 14;13(2):R43. doi: 10.1186/bcr2865.

6.

Med1 plays a critical role in the development of tamoxifen resistance.

Nagalingam A, Tighiouart M, Ryden L, Joseph L, Landberg G, Saxena NK, Sharma D.

Carcinogenesis. 2012 Apr;33(4):918-30. doi: 10.1093/carcin/bgs105. Epub 2012 Feb 16.

7.

AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.

Grabinski N, Möllmann K, Milde-Langosch K, Müller V, Schumacher U, Brandt B, Pantel K, Jücker M.

Cell Signal. 2014 May;26(5):1021-9. doi: 10.1016/j.cellsig.2014.01.018. Epub 2014 Jan 24.

PMID:
24463007
8.

Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling.

Thrane S, Lykkesfeldt AE, Larsen MS, Sorensen BS, Yde CW.

Breast Cancer Res Treat. 2013 May;139(1):71-80. doi: 10.1007/s10549-013-2485-2. Epub 2013 Apr 23.

PMID:
23609470
9.

Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.

Kurokawa H, Arteaga CL.

Clin Cancer Res. 2001 Dec;7(12 Suppl):4436s-4442s; discussion 4411s-4412s. Review.

PMID:
11916237
11.

Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.

Browne BC, Hochgräfe F, Wu J, Millar EK, Barraclough J, Stone A, McCloy RA, Lee CS, Roberts C, Ali NA, Boulghourjian A, Schmich F, Linding R, Farrow L, Gee JM, Nicholson RI, O'Toole SA, Sutherland RL, Musgrove EA, Butt AJ, Daly RJ.

FEBS J. 2013 Nov;280(21):5237-57. doi: 10.1111/febs.12441. Epub 2013 Aug 19.

PMID:
23876235
12.

Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.

Barone I, Brusco L, Gu G, Selever J, Beyer A, Covington KR, Tsimelzon A, Wang T, Hilsenbeck SG, Chamness GC, Andò S, Fuqua SA.

J Natl Cancer Inst. 2011 Apr 6;103(7):538-52. doi: 10.1093/jnci/djr058. Epub 2011 Mar 29.

13.

Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.

Cittelly DM, Das PM, Spoelstra NS, Edgerton SM, Richer JK, Thor AD, Jones FE.

Mol Cancer. 2010 Dec 20;9:317. doi: 10.1186/1476-4598-9-317.

14.

Silencing MED1 sensitizes breast cancer cells to pure anti-estrogen fulvestrant in vitro and in vivo.

Zhang L, Cui J, Leonard M, Nephew K, Li Y, Zhang X.

PLoS One. 2013 Jul 30;8(7):e70641. doi: 10.1371/journal.pone.0070641. Print 2013.

15.

Disruption of the ER-α36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells.

Yin L, Zhang XT, Bian XW, Guo YM, Wang ZY.

PLoS One. 2014 Sep 9;9(9):e107369. doi: 10.1371/journal.pone.0107369. eCollection 2014.

16.

A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers.

Parra-Palau JL, Pedersen K, Peg V, Scaltriti M, Angelini PD, Escorihuela M, Mancilla S, Sánchez Pla A, Ramón Y Cajal S, Baselga J, Arribas J.

Cancer Res. 2010 Nov 1;70(21):8537-46. doi: 10.1158/0008-5472.CAN-10-1701. Epub 2010 Oct 26.

18.

Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors.

Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME, Jones FE.

Carcinogenesis. 2010 Dec;31(12):2049-57. doi: 10.1093/carcin/bgq192. Epub 2010 Sep 27.

20.

Oncogenic MUC1-C promotes tamoxifen resistance in human breast cancer.

Kharbanda A, Rajabi H, Jin C, Raina D, Kufe D.

Mol Cancer Res. 2013 Jul;11(7):714-23. doi: 10.1158/1541-7786.MCR-12-0668. Epub 2013 Mar 28.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk